Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo

Cancer Gene Therapy

Volumn 18, Issue 11, 2011, Pages 773-784

  Harvey, T J ^a   Hennig, I M ^a   Shnyder, S D ^b   Cooper, P A ^b   Ingram, N ^a   Hall, G D ^a   Selby, P J ^a   Chester, J D ^a,c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

^c VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

adenovirus; EPO; HSVtk; hypoxia; NTR; VEGF

Indexed keywords

ADENOVIRUS VECTOR; BACTERIAL ENZYME; COBALT CHLORIDE; ERYTHROPOIETIN; GANCICLOVIR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 2; LUCIFERASE; NITROREDUCTASE; PRODRUG; THYMIDINE KINASE; TRETAZICAR; VASCULOTROPIN; VIRUS ENZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HCT116; CELL STRAIN HT1080; CONTROLLED STUDY; CYTOMEGALOVIRUS; FEMALE; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENE TARGETING; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; HYPOXIC CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SOLID TUMOR; SUICIDE GENE; TRANSGENE; TUMOR CELL LINE; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; GENE THERAPY; GENETIC VECTORS; HCT116 CELLS; HEK293 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; NITROREDUCTASES; PRODRUGS; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; BACTERIA (MICROORGANISMS); CYTOMEGALOVIRUS; MUS MUSCULUS; SIMPLEXVIRUS;

EID: 80054729738     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.43     Document Type: Article

References (44)

1. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000; 6: 157-162. (Pubitemid 30171366)
2. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metast Rev 2007; 26: 225-239. (Pubitemid 47101660)
3. Fechner G, Muller G, Schmidt D, Garbe S, Hauser S, Vaupel P et al. Evaluation of hypoxia-mediated growth factors in a novel bladder cancer animal model. Anticancer Res 2007; 27: 4225-4231.
4. Binley K, Askham Z, Iqball S, Spearman H, Martin L, de Alwis M et al. Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy. Blood 2002; 100: 2406-2413.
5. Chadderton N, Cowen RL, Sheppard FC, Robinson S, Greco O, Scott SD et al. Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cells. Int J Radiat Oncol Biol Phys 2005; 62: 213-222. (Pubitemid 40591945)
6. Koshikawa N, Takenaga K, Tagawa M, Sakiyama S. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res 2000; 60: 2936-2941. (Pubitemid 30395818)
7. Kaliberov SA, Buchsbaum DJ, Gillespie GY, Curiel DT, Arafat WO, Carpenter M et al. Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells. Mol Ther 2002; 6: 190-198. (Pubitemid 36336126)
8. Shibata T, Giaccia AJ, Brown JM. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia 2002; 4: 40-48. (Pubitemid 34075889)
9. Lee S, Kim K, Kim HA, Kim SW, Lee M. Augmentation of erythropoietin enhancer-mediated hypoxia-inducible gene expression by co-transfection of a plasmid encoding hypoxia-inducible factor 1alpha for ischemic tissue targeting gene therapy. J Drug Target 2008; 16: 43-50.
10. Okabe S, Arai T, Yamashita H, Sugihara K. Adenovirusmediated prodrug-enzyme therapy for CEA-producing colorectal cancer cells. J Cancer Res Clin Oncol 2003; 129: 367-373. (Pubitemid 36963200)
11. Ji X, Zhang J, Cheng L, Wei F, Li H, Liu X et al. Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model. Exp Eye Res 2009; 89: 193-199.
12. Dorer DE, Nettelbeck DM. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev 2009; 61: 554-571.
13. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 2001; 187: 22-36. (Pubitemid 32195242)
14. Wilson WR, Hicks KO, Pullen SM, Ferry DM, Helsby NA, Patterson AV. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Radiat Res 2007; 167: 625-636. (Pubitemid 351292942)
15. Nasu Y, Saika T, Ebara S, Kusaka N, Kaku H, Abarzua F et al. Suicide gene therapy with adenoviral delivery of HSVtK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther 2007; 15: 834-840. (Pubitemid 46432005)
16. Ahn M, Lee SJ, Li X, Jimenez JA, Zhang YP, Bae KH et al. Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter. Cancer Gene Ther 2009; 16: 73-82.
17. Patel P, Young JG, Mautner V, Ashdown D, Bonney S, Pineda RG et al. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1984. Mol Ther 2009; 17: 1292-1299.
18. Weedon SJ, Green NK, McNeish IA, Gilligan MG, Mautner V, Wrighton CJ et al. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. Int J Cancer 2000; 86: 848-854. (Pubitemid 30350201)
19. Jaberipour M, Vass SO, Guise CP, Grove JI, Knox RJ, Hu L et al. Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations. Biochem Pharmacol 2010; 79: 102-111.
20. Ingram N, MacCormac LP, Oxley NT, Burns PA, Hall GD. Role of cell surface molecules and autologous ascitic fluid in determining efficiency of adenoviral transduction of ovarian cancer cells. Cancer Gene Ther 2010; 17: 684-693.
21. Ahn GO, Brown M. Targeting tumors with hypoxiaactivated cytotoxins. Front Biosci 2007; 12: 3483-3501.
22. Greco O, Marples B, Joiner MC, Scott SD. How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J Cell Physiol 2003; 197: 312-325. (Pubitemid 37487030)
23. Palmer DH, Young LS, Mautner V. Cancer gene-therapy: clinical trials. Trends Biotechnol 2006; 24: 76-82. (Pubitemid 43151979)
24. Ingram N, Porter CD. Transcriptional targeting of acute hypoxia in the tumour stroma is a novel and viable strategy for cancer gene therapy. Gene Ther 2005; 12: 1058-1069. (Pubitemid 40946148)
25. Nishihara E, Nagayama Y, Narimatsu M, Namba H, Watanabe M, Niwa Met al. Treatment of thyroid carcinoma cells with four different suicide gene/prodrug combinations in vitro. Anticancer Res 1998; 18: 1521-1525. (Pubitemid 28342554)
26. Wilson WR, Pullen SM, Hogg A, Helsby NA, Hicks KO, Denny WA. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res 2002; 62: 1425-1432. (Pubitemid 34407802)
27. Heinkelein M, Hoffmann U, Lucke M, Imrich H, Muller JG, Meixensberger J et al. Experimental therapy of allogeneic solid tumors induced in athymic mice with suicide genetransducing replication-competent foamy virus vectors. Cancer Gene Ther 2005; 12: 947-953. (Pubitemid 41622261)
28. Aghi M, Hochberg F, Breakefield XO. Prodrug activation enzymes in cancer gene therapy. J Gene Med 2000; 2: 148-164.
29. Hayashi M, Sakata M, Takeda T, Yamamoto T, Okamoto Y, Sawada K et al. Induction of glucose transporter 1 expression through hypoxia-inducible factor 1alpha under hypoxic conditions in trophoblast-derived cells. J Endocrinol 2004; 183: 145-154. (Pubitemid 40124651)
30. Poulios E, Trougakos IP, Gonos ES. Comparative effects of hypoxia on normal and immortalized human diploid fibroblasts. Anticancer Res 2006; 26: 2165-2168. (Pubitemid 43989485)
31. Braidwood L, Dunn PD, Hardy S, Evans TR, Brown SM. Antitumor activity of a selectively replication competent herpes simplex virus (HSV) with enzyme prodrug therapy. Anticancer Res 2009; 29: 2159-2166.
32. White CL, Menghistu T, Twigger KR, Searle PF, Bhide SA, Vile RG et al. Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo. Gene Ther 2008; 15: 424-433. (Pubitemid 351331000)
33. Benouchan M, Do Nascimento F, Perret GY, Colombo BM. Delivery of the bacterial nitroreductase gene into endothelial cells prolongs the survival of tumour-bearing mice by bystander mechanisms. Int J Oncol 2006; 28: 457-462.
34. Lukashev AN, Fuerer C, Chen MJ, Searle P, Iggo R. Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954. Hum Gene Ther 2005; 16: 1473-1483. (Pubitemid 41829022)
35. Chen MJ, Green NK, Reynolds GM, Flavell JR, Mautner V, Kerr DJ et al. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. Gene Ther 2004; 11: 1126-1136. (Pubitemid 39117308)
36. Post DE, Sandberg EM, Kyle MM, Devi NS, Brat DJ, Xu Z et al. Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res 2007; 67: 6872-6881. (Pubitemid 47105534)
37. Cho WK, Seong YR, Lee YH, Kim MJ, Hwang KS, Yoo J et al. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. Mol Ther 2004; 10: 938-949. (Pubitemid 39419919)
38. Post DE, Van Meir EG. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther 2001; 8: 1801-1807. (Pubitemid 34100581)
39. Vassaux G, Hurst HC, Lemoine NR. Insulation of a conditionally expressed transgene in an adenoviral vector. Gene Ther 1999; 6: 1192-1197. (Pubitemid 29295228)
40. Ring CJ, Harris JD, Hurst HC, Lemoine NR. Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Gene Ther 1996; 3: 1094-1103. (Pubitemid 27036113)
41. Plumb J, Norlin C, Young PC. Exposures and outcomes of children with urticaria seen in a pediatric practice-based research network: a case-control study. Arch Pediatr Adolesc Med 2001; 155: 1017-1021. (Pubitemid 32824046)
42. Andrews PA, Jones JA. Characterization of binding proteins from ovarian carcinoma and kidney tubule cells that are specific for cisplatin modified DNA. Cancer Commun 1991; 3: 93-102.
43. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J et al. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer 1998; 77: 1-10. (Pubitemid 28029765)
44. Shnyder SD, Cooper PA, Pettit GR, Lippert III JW, Bibby MC. Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model. Anticancer Res 2003; 23: 1619-1623. (Pubitemid 36754137)